---
id: medra-ai-robotics
slug: medra-ai-robotics
entity_type: commercial
status: operational
data_completeness: very_high
last_researched: 2025-12-23
researcher: AI Assistant
version: 2.1
name: Medra AI-Robotics Platform
description: "Medra develops the world's first Continuous Science Platform that integrates Physical AI (robotics) and Scientific AI (reasoning models) to autonomously conduct laboratory experiments, accelerating scientific data generation and discovery in life sciences. The platform enables 24/7 autonomous iteration, learning from failures in real-time, and compressing decades of discovery into months."
mission: "To develop the world's first Continuous Science Platform that integrates Physical AI (robotics) and Scientific AI (reasoning models) to autonomously conduct laboratory experiments, accelerating scientific data generation and discovery in life sciences. The platform aims to enable 24/7 autonomous iteration, learning from failures in real-time, and compressing decades of discovery into months."
entity_data:
  focus: Development of autonomous AI-powered laboratory systems integrating robotics and AI to accelerate scientific data generation and discovery
  founded: 2022
  website: "https://www.medra.ai/"
  industry: Life Sciences Technology
  employees:
  note: Exact employee count not publicly disclosed
  as_of: 2025-12
  legal_name: Medra Inc.
taxonomy:
  geography: USA
  ai_approach: []
  ai_technology:
  - Transformers
  - Multi-Agent AI
  primary_focus:
  - Robotic Lab Automation
  aging_approach:
  - Senescent Cell Elimination
  target_biology:
  - General Aging/Longevity
  ai_architecture:
  - Transformers
  ai_specialization:
  - Multi-Agent AI
  development_stage: Operational
  therapeutic_modality: []
organizations:
  -
    name: Human Capital
    role: partner
    org_type: company
    status: operational
    role_description: Lead investor
    contribution_description: "Lead investor in Medra's $52 million Series A funding round (December 2025)"
  -
    name: Fusion Fund
    role: partner
    org_type: company
    status: operational
    role_description: Investor
    contribution_description: "Investor in Medra's $52 million Series A funding round (December 2025)"
  -
    name: Lux Capital
    role: partner
    org_type: company
    status: operational
    role_description: Investor
    contribution_description: "Investor in Medra's $52 million Series A funding round (December 2025)"
  -
    name: Addition Therapeutics
    role: partner
    org_type: company
    status: operational
    role_description: Technology partner
    contribution_description: "Utilizing Medra's platform to support gene editing work. Results include: reduced control variance from 36.6% to 3.7% in one month, improved transfection efficiency by up to 35%, tripled weekly throughput, and saved researchers an estimated 50 hours of manual work per week."
  -
    name: 776
    role: partner
    org_type: company
    status: operational
    role_description: Investor
    contribution_description: "Investor in Medra's $52 million Series A funding round (December 2025)"
  -
    name: Medra
    role: primary
    org_type: company
    legal_name: Medra Inc.
    founded: 2022
    website: "https://www.medra.ai/"
    status: operational
    role_description: Primary organization - Medra Inc. is the company developing the Continuous Science Platform
    contribution_description: Medra Inc. is the primary organization developing and deploying the Continuous Science Platform that integrates Physical AI and Scientific AI for autonomous laboratory experimentation
  -
    name: Genentech
    role: partner
    org_type: company
    status: operational
    role_description: Strategic partner
    contribution_description: "Collaborating to integrate Medra's Physical AI and Scientific AI into Genentech's laboratory information management systems (LIMS) and machine learning infrastructure. The partnership enables a closed-loop workflow: internal predictions, automated experiments, and iterative optimization without human intervention, accelerating drug discovery processes."
  -
    name: Lila Sciences
    role: partner
    org_type: company
    status: operational
    role_description: Technology partner
    contribution_description: Collaborated to fully automate workflows involving the LabChip GX Touch device. Achieved full automation within 3 months, scaled from 12 to 384 samples without hardware changes, and reduced deployment timelines from over 12 months to 3 months.
  -
    name: Menlo Ventures
    role: partner
    org_type: company
    status: operational
    role_description: Investor
    contribution_description: "Investor in Medra's $52 million Series A funding round (December 2025)"
  -
    name: Neo
    role: partner
    org_type: company
    status: operational
    role_description: Investor
    contribution_description: "Investor in Medra's $52 million Series A funding round (December 2025)"
  -
    name: Cultivarium
    role: partner
    org_type: company
    status: operational
    role_description: Research partner
    contribution_description: "Partnering to advance scientific discovery through the integration of Medra's Continuous Science Platform into Cultivarium's research workflows, focusing on microbial discovery."
  -
    name: NFDG
    role: partner
    org_type: company
    status: operational
    role_description: Investor
    contribution_description: "Investor in Medra's $52 million Series A funding round (December 2025)"
  -
    name: Catalio Capital Management
    role: partner
    org_type: company
    status: operational
    role_description: Investor
    contribution_description: "Investor in Medra's $52 million Series A funding round (December 2025)"
products:
  -
    name: Continuous Science Platform
    type: platform
    status: Operational
    development_stage: Operational
links:
  -
    url: "https://longevity.technology/news/can-physical-ai-help-accelerate-longevity-drug-development/"
    type: article
    title: Can Physical AI Help Accelerate Longevity Drug Development?
  -
    url: "https://www.medra.ai/about"
    type: website
    title: Medra About Page
  -
    url: "https://www.medra.ai/series-a"
    type: website
    title: Medra Series A Announcement
  -
    url: "https://www.medra.ai/lila-case-study"
    type: case_study
    title: "From Automation to AI: The Future of Labs - Lila Sciences Case Study"
  -
    url: "https://www.mobihealthnews.com/news/medra-raises-52m-partners-genentech"
    type: news_article
    title: Medra Raises $52M, Partners with Genentech
  -
    url: "https://www.investing.com/news/company-news/medra-raises-52-million-to-build-autonomous-aipowered-lab--bloomberg-93CH-4403537"
    type: news_article
    title: Medra Raises $52 Million to Build Autonomous AI-Powered Lab
  -
    url: "https://www.businesswire.com/news/home/20251211748411/en/Medra-Raises-%2452-Million-Series-A-to-Build-Physical-AI-Scientists"
    type: press_release
    title: Medra Raises $52 Million Series A to Build Physical AI Scientists
  -
    url: "https://www.bloomberg.com/news/articles/2025-12-11/medra-raises-52-million-to-speed-drug-discovery-with-ai-robots"
    type: news_article
    title: Medra Raises $52 Million to Speed Drug Discovery With AI Robots
  -
    url: "https://www.medra.ai/launch"
    type: website
    title: Medra Platform Launch Page
  -
    url: "https://medra-ai.webflow.io/"
    type: website
    title: Medra - Hand over lab work
  -
    url: "https://hlth.com/insights/news/medra-raises-52m-partners-with-genentech-2025-12-15"
    type: news_article
    title: Medra Raises $52M, Partners With Genentech
  -
    url: "https://www.biopharmatrend.com/post/1377-medra-launches-ai-driven-platform-for-continuous-scientific-experimentation/"
    type: news_article
    title: Medra Launches AI-Driven Platform for Continuous Scientific Experimentation - BioPharmaTrend
  -
    url: "https://www.businesswire.com/news/home/20250912829200/en/Medra-Launches-Continuous-Science-Platform-to-Power-the-Scientific-Frontier"
    type: press_release
    title: Medra Launches Continuous Science Platform to Power the Scientific Frontier
  -
    url: "https://www.roboticstomorrow.com/news/2025/12/11/medra-raises-52-million-series-a-to-build-physical-ai-scientists/25907"
    type: news_article
    title: Medra Raises $52 Million Series A to Build Physical AI Scientists - Robotics Tomorrow
---

# Medra AI-Robotics Platform

## Description

Medra develops the world's first Continuous Science Platform that integrates Physical AI (robotics) and Scientific AI (reasoning models) to autonomously conduct laboratory experiments, accelerating scientific data generation and discovery in life sciences. The platform enables 24/7 autonomous iteration, learning from failures in real-time, and compressing decades of discovery into months.

## Mission

To develop the world's first Continuous Science Platform that integrates Physical AI (robotics) and Scientific AI (reasoning models) to autonomously conduct laboratory experiments, accelerating scientific data generation and discovery in life sciences. The platform aims to enable 24/7 autonomous iteration, learning from failures in real-time, and compressing decades of discovery into months.

## Company Information

**Legal Name**: Medra Inc.
**Founded**: 2022
**Industry**: Life Sciences Technology
**Employees**: {"note":"Exact employee count not publicly disclosed","as_of":"2025-12"}
**Focus**: Development of autonomous AI-powered laboratory systems integrating robotics and AI to accelerate scientific data generation and discovery
**Website**: https://www.medra.ai/

## AI Methods

- Reinforcement Learning (RL)-driven closed-loop system
- Robotics integration with agentic models
- Multi-modal reasoning across unstructured data, images, protocols, and results
- Natural language processing for protocol programming
- Computer vision for error detection and recovery

## Lessons Learned

### Achievements

- Successfully developed and deployed the first Continuous Science Platform integrating Physical AI and Scientific AI
- Demonstrated 100x acceleration in senolytic discovery throughput
- Achieved full automation of complex workflows (e.g., Lila Sciences case: 3 months vs. 12+ months)
- Enabled scaling from 12 to 384 samples without hardware changes
- Reduced experimental variance significantly (e.g., Addition Therapeutics: 36.6% to 3.7%)
- Established partnerships with major pharmaceutical companies (Genentech) and research organizations
- Raised $52 million Series A funding from top-tier investors

### Impact on Field

Medra's platform represents a significant advancement in autonomous laboratory systems. By combining robotics with AI reasoning, it addresses the critical bottleneck of slow, human-dependent drug screening. The demonstrated 100x acceleration in senolytic discovery throughput and ability to compress lab phases by 3-5 years shows transformative potential for longevity research and drug discovery more broadly. The platform enables qualitatively new experiments through 24/7 autonomous iteration and real-time learning from failures.

## Organizations

### Human Capital
**Role in Project**: partner
**Role Description**: Lead investor
**Contribution**: Lead investor in Medra's $52 million Series A funding round (December 2025)
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm, lead investor in Medra's $52 million Series A funding round
**Focus**: Venture Capital, Investment

### Fusion Fund
**Role in Project**: partner
**Role Description**: Investor
**Contribution**: Investor in Medra's $52 million Series A funding round (December 2025)
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm, investor in Medra's Series A funding round
**Focus**: Venture Capital, Investment

### Lux Capital
**Role in Project**: partner
**Role Description**: Investor
**Contribution**: Investor in Medra's $52 million Series A funding round (December 2025)
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm focused on emerging science and technology
**Focus**: Venture capital, science and technology investment

### Addition Therapeutics
**Role in Project**: partner
**Role Description**: Technology partner
**Contribution**: Utilizing Medra's platform to support gene editing work. Results include: reduced control variance from 36.6% to 3.7% in one month, improved transfection efficiency by up to 35%, tripled weekly throughput, and saved researchers an estimated 50 hours of manual work per week.
**Organization Type**: company
**Status**: operational
**Description**: Biotechnology company utilizing Medra's platform to support gene editing work
**Focus**: Gene Editing, Biotechnology

### 776
**Role in Project**: partner
**Role Description**: Investor
**Contribution**: Investor in Medra's $52 million Series A funding round (December 2025)
**Organization Type**: company
**Status**: operational
**Description**: Investment firm, investor in Medra's Series A funding round
**Focus**: Investment, Venture Capital

### Medra
**Legal Name**: Medra Inc.
**Role in Project**: primary
**Role Description**: Primary organization - Medra Inc. is the company developing the Continuous Science Platform
**Contribution**: Medra Inc. is the primary organization developing and deploying the Continuous Science Platform that integrates Physical AI and Scientific AI for autonomous laboratory experimentation
**Organization Type**: company
**Status**: operational
**Founded**: 2022
**Website**: https://www.medra.ai/
**Description**: Medra develops autonomous AI-powered laboratory systems integrating robotics and AI to accelerate scientific data generation and discovery. The company's Continuous Science Platform combines Physical AI (robotics) and Scientific AI (reasoning models) to create a closed-loop, self-improving system for autonomous laboratory experimentation.
**Focus**: Development of autonomous AI-powered laboratory systems integrating robotics and AI to accelerate scientific data generation and discovery

### Genentech
**Role in Project**: partner
**Role Description**: Strategic partner
**Contribution**: Collaborating to integrate Medra's Physical AI and Scientific AI into Genentech's laboratory information management systems (LIMS) and machine learning infrastructure. The partnership enables a closed-loop workflow: internal predictions, automated experiments, and iterative optimization without human intervention, accelerating drug discovery processes.
**Organization Type**: company
**Status**: operational
**Description**: Genentech is a biotechnology company and member of the Roche Group, focused on developing medicines for serious and life-threatening diseases.
**Focus**: Biotechnology, Drug Discovery

### Lila Sciences
**Role in Project**: partner
**Role Description**: Technology partner
**Contribution**: Collaborated to fully automate workflows involving the LabChip GX Touch device. Achieved full automation within 3 months, scaled from 12 to 384 samples without hardware changes, and reduced deployment timelines from over 12 months to 3 months.
**Organization Type**: company
**Status**: operational
**Description**: Company collaborating with Medra to fully automate workflows involving the LabChip GX Touch device
**Focus**: Protein Characterization, Automation

### Menlo Ventures
**Role in Project**: partner
**Role Description**: Investor
**Contribution**: Investor in Medra's $52 million Series A funding round (December 2025)
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm
**Focus**: Venture capital, technology investment

### Neo
**Role in Project**: partner
**Role Description**: Investor
**Contribution**: Investor in Medra's $52 million Series A funding round (December 2025)
**Organization Type**: company
**Status**: operational
**Description**: Venture capital firm, investor in Medra's Series A funding round
**Focus**: Venture Capital, Investment

### Cultivarium
**Role in Project**: partner
**Role Description**: Research partner
**Contribution**: Partnering to advance scientific discovery through the integration of Medra's Continuous Science Platform into Cultivarium's research workflows, focusing on microbial discovery.
**Organization Type**: company
**Status**: operational
**Description**: Research organization partnering with Medra to advance scientific discovery through the integration of Medra's Continuous Science Platform
**Focus**: Microbial Discovery, Research

### NFDG
**Role in Project**: partner
**Role Description**: Investor
**Contribution**: Investor in Medra's $52 million Series A funding round (December 2025)
**Organization Type**: company
**Status**: operational
**Description**: Investment firm, investor in Medra's Series A funding round
**Focus**: Investment, Venture Capital

### Catalio Capital Management
**Role in Project**: partner
**Role Description**: Investor
**Contribution**: Investor in Medra's $52 million Series A funding round (December 2025)
**Organization Type**: company
**Status**: operational
**Description**: Investment firm, investor in Medra's Series A funding round
**Focus**: Investment, Venture Capital

## Locations

### Medra Headquarters
**Type**: headquarters
**Address**: San Francisco, California
**City**: San Francisco
**State/Region**: California
**Country**: USA
**Organizations**: Medra

## Products

### Continuous Science Platform
**Alternative Names**: Medra AI-Robotics Platform, Physical AI Scientists Platform
**Type**: platform
**Status**: Operational
**Development Stage**: Operational
**Role in Project**: primary
**Relationship Description**: Continuous Science Platform is the primary product developed by Medra, integrating Physical AI and Scientific AI for autonomous laboratory experimentation
**Description**: Autonomous laboratory system that integrates Physical AI (autonomous robotic system) with Scientific AI (reasoning models) to create a closed-loop, self-improving system that autonomously executes laboratory protocols, analyzes results, and optimizes experimental designs
**Mechanism of Action**: Integrates Physical AI (autonomous robotic system) with Scientific AI (reasoning models) to create a closed-loop, self-improving system that autonomously executes laboratory protocols, analyzes results, and optimizes experimental designs
**Target**: Laboratory automation and scientific discovery acceleration
**Pathway**: Autonomous experimentation with closed-loop optimization
**Capabilities**:
- Natural language programming
- Multi-modal reasoning across unstructured data, images, protocols, and results
- Closed-loop optimization
- Instrument agnostic integration
- Error detection and recovery
- Flexibility and modularity
**Applications**:
- Gene editing (CRISPR-Cas9)
- Microbial discovery
- Protein purification
- RNA transfection
- Suspension cell culture
- Nucleic acid extraction
- Drug discovery
- Antibody workflows
- Cell-based assays
**Indications**: [
  {
    "primary": "Longevity drug discovery (senolytic discovery mentioned in case study)",
    "secondary": [
      "General drug discovery",
      "Gene therapy development",
      "Protein engineering",
      "Cell-based research"
    ]
  }
]
**Components**:
```yaml
-
  name: Physical AI
  description: "Autonomous robotic system that executes laboratory protocols using general-purpose robots equipped with visual and language understanding. Captures detailed data on every action (images, logs, metadata) creating a new metadata layer called 'Infra-data'. Interfaces with standard laboratory tools and instruments, enabling flexible automation of up to 70% of tools scientists use."
  technical_details:
  deployment: Five systems currently deployed at partner sites across the United States
  flexibility: Can adapt to various experimental tasks and protocols without requiring specialized equipment
  computer_vision: Equipped with computer vision for error detection and automatic protocol recovery
  infra_data_capture: Captures unprecedented granularity of experimental data including pipette angles, mixing times, reagent volumes, and timing information for each protocol step
-
  name: Scientific AI
  description: AI system that analyzes Infra-data alongside data from electronic lab notebooks or scientific literature. Utilizes reasoning models to suggest new experimental actions and protocol optimizations. Forms a closed-loop, self-improving system that converges on optimal protocols faster than traditional methods.
  technical_details:
  architecture: Reasoning models with multi-modal capabilities (specific architecture proprietary)
  learning_approach: 24/7 autonomous iteration with real-time learning from experimental failures
  reinforcement_learning: RL-driven closed-loop system for iterative testing and optimization
  natural_language_processing: NLP for protocol programming via natural language (written or voice commands)
```
**Technical Details**:
```yaml
notes: The platform has demonstrated significant acceleration in senolytic discovery (100x throughput improvement) as mentioned in longevity.technology case study. The system enables autonomous iteration and real-time learning, compressing traditional lab phases by 3-5 years.
case_studies:
  -
    date: 2025
    partner: Addition Therapeutics
    results:
    time_saved: Estimated 50 hours of manual work per week saved for researchers
    throughput_increase: Tripled weekly throughput
    control_variance_reduction: Reduced from 36.6% to 3.7% in one month
    transfection_efficiency_improvement: Up to 35% improvement
    description: "Optimized RNA transfection experiments using Medra's platform"
  -
    date: 2025-09
    partner: Lila Sciences
    results:
    scalability: Scaling from 12 to 384 samples without hardware changes
    automation_achievement: Full automation within 3 months
    deployment_time_reduction: Reduced from over 12 months to 3 months
    description: Automated protein characterization using the LabChip GX Touch device
  -
    date: 2025-12
    partner: Genentech
    results:
    workflow: "Closed-loop workflow: internal predictions, automated experiments, and iterative optimization without human intervention"
    description: "Integration of Medra's Physical AI and Scientific AI into Genentech's laboratory systems to enable closed-loop workflow for drug discovery"
regulatory_status: Platform technology - not subject to drug regulatory approval
performance_metrics:
  autonomy: 24/7 autonomous iteration with real-time learning from failures
  scalability: Scaling from 12 to 384 samples without hardware changes (Lila Sciences case study)
  daily_capacity: Enables thousands of variants to be tested daily
  deployment_time: Reduced deployment timelines from over 12 months to 3 months (Lila Sciences case study)
  error_reduction: Detects errors with computer vision and resumes protocols
  time_compression: Compresses lab phases by 3-5 years
  throughput_acceleration: 100x acceleration in senolytic discovery throughput (as mentioned in case study)
```

## Key People

### Michelle Lee
**Title**: PhD
**Participation Type**: leadership
**Role in Project**: CEO, Co-founder
**Participation Period**: 2022-present
**Contribution**: CEO and Co-founder leading Medra's strategic direction and platform development
**Expertise**: Robotics, AI, autonomous systems
**Biography**: PhD in robotics from Stanford University, founded Medra in 2022 after leaving planned academic career at New York University

## Links

### [Can Physical AI Help Accelerate Longevity Drug Development?](https://longevity.technology/news/can-physical-ai-help-accelerate-longevity-drug-development/)
**Type**: article
**Publisher**: longevity.technology
**Publication Date**: 2025-12-01
**Description**: Article discussing Medra's platform in context of longevity drug discovery, mentioning 100x acceleration in senolytic discovery throughput and RL-driven closed-loop system

### [Medra About Page](https://www.medra.ai/about)
**Type**: website
**Publisher**: Medra
**Description**: Information about Medra's team and company background

### [Medra Series A Announcement](https://www.medra.ai/series-a)
**Type**: website
**Publisher**: Medra
**Publication Date**: 2025-12-11
**Description**: Official Series A funding announcement page

### [From Automation to AI: The Future of Labs - Lila Sciences Case Study](https://www.medra.ai/lila-case-study)
**Type**: case_study
**Publisher**: Medra
**Publication Date**: 2025-09-11
**Description**: Case study detailing collaboration with Lila Sciences for protein characterization automation

### [Medra Raises $52M, Partners with Genentech](https://www.mobihealthnews.com/news/medra-raises-52m-partners-genentech)
**Type**: news_article
**Publisher**: MobiHealthNews
**Publication Date**: 2025-12-11
**Description**: MobiHealthNews coverage of funding and partnership announcement

### [Medra Raises $52 Million to Build Autonomous AI-Powered Lab](https://www.investing.com/news/company-news/medra-raises-52-million-to-build-autonomous-aipowered-lab--bloomberg-93CH-4403537)
**Type**: news_article
**Publisher**: Bloomberg via Investing.com
**Publication Date**: 2025-12-11
**Description**: Bloomberg news coverage via Investing.com of Series A funding announcement

### [Medra Raises $52 Million Series A to Build Physical AI Scientists](https://www.businesswire.com/news/home/20251211748411/en/Medra-Raises-%2452-Million-Series-A-to-Build-Physical-AI-Scientists)
**Type**: press_release
**Publisher**: Business Wire
**Publication Date**: 2025-12-11
**Description**: Official press release announcing $52 million Series A funding round and Genentech partnership

### [Medra Raises $52 Million to Speed Drug Discovery With AI Robots](https://www.bloomberg.com/news/articles/2025-12-11/medra-raises-52-million-to-speed-drug-discovery-with-ai-robots)
**Type**: news_article
**Publisher**: Bloomberg
**Publication Date**: 2025-12-11
**Description**: Bloomberg news article about Medra's Series A funding

### [Medra Platform Launch Page](https://www.medra.ai/launch)
**Type**: website
**Publisher**: Medra
**Publication Date**: 2025-09-12
**Description**: Physical AI in the Lab: Unlocking Data for Scientific Breakthroughs - platform launch information

### [Medra - Hand over lab work](https://medra-ai.webflow.io/)
**Type**: website
**Publisher**: Medra
**Description**: Alternative Medra website with platform information

### [Medra Raises $52M, Partners With Genentech](https://hlth.com/insights/news/medra-raises-52m-partners-with-genentech-2025-12-15)
**Type**: news_article
**Publisher**: HLTH
**Publication Date**: 2025-12-15
**Description**: HLTH news coverage of Series A funding and Genentech partnership

### [Medra Launches AI-Driven Platform for Continuous Scientific Experimentation - BioPharmaTrend](https://www.biopharmatrend.com/post/1377-medra-launches-ai-driven-platform-for-continuous-scientific-experimentation/)
**Type**: news_article
**Publisher**: BioPharmaTrend
**Publication Date**: 2025-09-01
**Description**: Biopharma industry news about platform launch and case studies with Addition Therapeutics

### [Medra Launches Continuous Science Platform to Power the Scientific Frontier](https://www.businesswire.com/news/home/20250912829200/en/Medra-Launches-Continuous-Science-Platform-to-Power-the-Scientific-Frontier)
**Type**: press_release
**Publisher**: Business Wire
**Publication Date**: 2025-09-12
**Description**: Official press release announcing the launch of Continuous Science Platform

### [Medra Raises $52 Million Series A to Build Physical AI Scientists - Robotics Tomorrow](https://www.roboticstomorrow.com/news/2025/12/11/medra-raises-52-million-series-a-to-build-physical-ai-scientists/25907)
**Type**: news_article
**Publisher**: Robotics Tomorrow
**Publication Date**: 2025-12-11
**Description**: Robotics industry news coverage of Series A funding announcement

## Financials

### funding
**Amount**: $52 million USD
**Amount (Numeric)**: 52000000
**Funding Date**: 2025-12-11
**Funding Type**: Series A
**Description**: Series A funding round led by Human Capital to build Physical AI Scientists platform and expand operations
**Details**:
```yaml
note: Total funding includes Series A round. Previous funding rounds (if any) not publicly disclosed.
investors:
  - Human Capital (lead investor)
  - Lux Capital
  - Neo
  - NFDG
  - Catalio Capital Management
  - Menlo Ventures
  - 776
  - Fusion Fund
valuation: Not disclosed
use_of_funds: To build Physical AI Scientists platform and expand operations
total_funding: $63 million
total_funding_numeric: 63000000
```

## Events

### Company Founded
**Date**: 2022-01-01
**Type**: foundation
**Description**: Medra Inc. founded by Michelle Lee in San Francisco, California
**Details**:
```yaml
founder: Michelle Lee
location: San Francisco, California
```

### Platform Launch
**Date**: 2025-09-12
**Type**: launch
**Description**: Medra launched its Continuous Science Platform to power the scientific frontier, integrating robotics and AI to accelerate scientific data generation and discovery

### Deployment Milestone
**Date**: 2025-12-01
**Type**: milestone
**Description**: Five Medra systems deployed at partner sites across the United States, including Genentech and Addition Therapeutics
**Details**:
```yaml
partners:
  - Genentech
  - Addition Therapeutics
deployment_count: 5
```

### Series A Funding
**Date**: 2025-12-11
**Type**: funding
**Description**: Medra raised $52 million Series A financing led by Human Capital to develop the first platform for Physical AI Scientists. Announced partnership with Genentech to integrate Medra's platform into Genentech's laboratory systems
**Details**:
```yaml
amount: $52 million
lead_investor: Human Capital
partnership_announcement: Genentech partnership announced
```

### Autonomous Laboratory Launch (Planned)
**Date**: 2026-01-01
**Type**: launch
**Description**: Plans to build one of the largest autonomous laboratories in the US, equipped with approximately 100 robots, in the San Francisco Bay Area
**Details**:
```yaml
status: planned
location: San Francisco Bay Area
timeline: 2026
robot_count: 100
```

## Partnerships

### strategic
**Date**: 2025-12-11
**Focus**: Drug discovery acceleration
**Description**: Collaborating to integrate Medra's Physical AI and Scientific AI into Genentech's laboratory information management systems (LIMS) and machine learning infrastructure. The partnership enables a closed-loop workflow: internal predictions, automated experiments, and iterative optimization without human intervention, accelerating drug discovery processes.
**Partner Organizations**:
- Medra (partner)
  - Medra providing Physical AI and Scientific AI platform
- Genentech (partner)
  - Strategic partner integrating Medra's platform into Genentech's laboratory systems
**Details**:
```yaml
workflow: "Closed-loop workflow: internal predictions, automated experiments, and iterative optimization without human intervention"
```

### technology
**Date**: 2025-09-01
**Focus**: Protein characterization automation
**Description**: Collaborated to fully automate workflows involving the LabChip GX Touch device. Achieved full automation within 3 months, scaled from 12 to 384 samples without hardware changes, and reduced deployment timelines from over 12 months to 3 months.
**Partner Organizations**:
- Medra (partner)
  - Medra providing automation platform
- Lila Sciences (partner)
  - Technology partner for protein characterization automation
**Details**:
```yaml
results:
  scalability: Scaling from 12 to 384 samples without hardware changes
  automation_achievement: Full automation within 3 months
  deployment_time_reduction: Reduced from over 12 months to 3 months
```

### research
**Date**: 2025-01-01
**Focus**: Microbial discovery
**Description**: Partnering to advance scientific discovery through the integration of Medra's Continuous Science Platform into Cultivarium's research workflows
**Partner Organizations**:
- Medra (partner)
  - Medra providing Continuous Science Platform
- Cultivarium (partner)
  - Research partner integrating Medra's platform

### technology
**Date**: 2025-01-01
**Focus**: Gene editing optimization
**Description**: Utilizing Medra's platform to support gene editing work. Results include: reduced control variance from 36.6% to 3.7% in one month, improved transfection efficiency by up to 35%, tripled weekly throughput, and saved researchers an estimated 50 hours of manual work per week.
**Partner Organizations**:
- Medra (partner)
  - Medra providing platform technology
- Addition Therapeutics (partner)
  - Technology partner utilizing Medra's platform for gene editing
**Details**:
```yaml
results:
  time_saved: Estimated 50 hours of manual work per week saved for researchers
  throughput_increase: Tripled weekly throughput
  control_variance_reduction: Reduced from 36.6% to 3.7% in one month
  transfection_efficiency_improvement: Up to 35% improvement
```
